CD7 and acute lymphoblastic leukemia: Recently, in a pioneering first-in-human phase I trial (NCT04572308), naturally selected CD7 CAR-T-cell immunotherapy was applied to 20 patients with R/R T-cell acute lymphoblastic leukemia (T-ALL, n=14) and lymphoblastic lymphoma (T-LBL, n=6).